9AV-61618-15349
3 vaccinations
1 coded response
15 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 05-11
- ZIP prefix
- 352 / AL
- Registered
- 2021-12-30
- Relationship
- Child or adolescent in my care
- Guardian
- 5SR-92173-38194
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-11-23
Dose 1 — Pfizer-BioNTech
-
2021-12-15
Dose 2 — Pfizer-BioNTech
-
2021-12-30
Registered in v-safe
- 2021-12-30
- 2022-01-05
- 2022-01-12
- 2022-01-19
- 2022-01-26
- 2022-03-16
-
2022-06-13
Dose 3 — Pfizer-BioNTech
- 2022-06-15
- 2022-06-20
- 2022-06-27
- 2022-07-04
- 2022-07-11
- 2022-07-18
- 2022-07-25
-
2022-09-12
Survey response — 3 months, dose 3, dependentMedDRA: Abdominal pain upper, Headache, Nausea, Pyrexia, Urticaria — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Stomach ache, nausea, hives, headache, fever.MedDRA releases: 2024-11 · check-in free text available
- 2022-12-14
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-11-23 | Pfizer-BioNTech | No |
| 2 | 2021-12-15 | Pfizer-BioNTech | No |
| 3 | 2022-06-13 | Pfizer-BioNTech | No |
Free text
Release 12 — 3 months, dose 3, dependent
Symptoms: Stomach ache, nausea, hives, headache, fever.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Abdominal pain upper | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Nausea | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Urticaria | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release